Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

ProKidney Corp. - Class A Ordinary Shares (NQ: PROK )

2.730 -0.240 (-8.08%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jun 14, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 443,185
Open 2.940
Bid (Size) 2.850 (10)
Ask (Size) 2.910 (5)
Prev. Close 2.970
Today's Range 2.715 - 3.047
52wk Range 1.120 - 13.51
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
ProKidney Announces Pricing of its Upsized $130 Million Public Offering of Class A Ordinary Shares and Concurrent Registered Direct Offering
From ProKidney
Via GlobeNewswire
Why Contango Ore Shares Are Trading Lower By 18%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Via Benzinga

Performance

YTD
+59.65%
+59.65%
1 Month
-30.36%
-30.36%
3 Month
+93.62%
+93.62%
6 Month
+53.37%
+53.37%
1 Year
-75.73%
-75.73%

More News

Read More
PROK Stock Earnings: ProKidney Beats EPS for Q1 2024
Via InvestorPlace
12 Health Care Stocks Moving In Tuesday's Intraday Session
Via Benzinga
Why Calavo Growers Shares Are Trading Higher By 12%; Here Are 20 Stocks Moving Premarket
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
Via InvestorPlace
12 Health Care Stocks Moving In Monday's After-Market Session
Via Benzinga
ProKidney Announces Proposed $125 Million Public Offering of Class A Ordinary Shares and Concurrent Registered Direct Offering
From ProKidney
Via GlobeNewswire
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday
Via InvestorPlace
ProKidney Announces Positive Interim REGEN-007 Phase 2 Trial Data and Provides Clinical and Operational Updates
From ProKidney
Via GlobeNewswire
ProKidney to Participate in the Jefferies Global Healthcare Conference
From ProKidney
Via GlobeNewswire
ProKidney to Host Virtual KOL Event to Discuss Current Treatment Landscape of Chronic Kidney Disease Caused by Diabetes and Data from Phase 2 RMCL-002 Clinical Trial on May 28, 2024
From ProKidney
Via GlobeNewswire
12 Health Care Stocks Moving In Tuesday's Intraday Session
Via Benzinga
ProKidney Reports Business Updates and First Quarter 2024 Financial Results
From ProKidney
Via GlobeNewswire
12 Health Care Stocks Moving In Monday's Intraday Session
Via Benzinga
12 Health Care Stocks Moving In Wednesday's After-Market Session
Via Benzinga
Why Ultragenyx Pharmaceutical Shares Are Trading Lower By Around 9%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Via Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session
Via Benzinga
ProKidney Announces Key Leadership Appointments Strengthening Clinical and Technical Operations
From ProKidney
Via GlobeNewswire
12 Health Care Stocks Moving In Friday's After-Market Session
Via Benzinga
ProKidney to Participate in Jefferies Biotech on the Bay Summit
From ProKidney
Via GlobeNewswire
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Via Benzinga
12 Health Care Stocks Moving In Friday's After-Market Session
Via Benzinga
ProKidney Appoints Nikhil Pereira-Kamath, MBA, as Chief Business Officer
From ProKidney
Via GlobeNewswire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.